Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
ANN ARBOR, Mich. and CAMBRIDGE, Mass., Feb. 14, 2012 /PRNewswire-USNewswire/ -- Compendia Bioscience today announced that it has signed a three-year licensing agreement with H3 Biomedicine, Inc. to Compendia's full suite of Oncomine tools including Oncomine Concepts Edition and Oncomine Power Tools Edition.
In addition, Compendia and H3 will work together to mine data from The Cancer Genome Atlas (TCGA) to discover novel therapeutic targets and biomarkers to support drug development.
"We are really excited to welcome H3 Biomedicine as a new partner and customer," said Daniel Rhodes, Ph.D., Compendia's co-founder and CEO. "H3 has developed a unique and compelling business strategy that is perfectly aligned with Compendia's vision for cancer drug discovery and development. We could not be more pleased to be working with them to make their vision into a reality."
"Compendia is the clear and recognized industry leader in applying cancer genomics to the discovery and development of cancer therapeutics," said Dr. Markus Warmuth, the CEO of H3 Biomedicine. "As we aim to develop H3 into a potent cancer drug discovery enterprise, it is clear that we need to partner with companies such as Compendia that think about cancer in the same way we do, that believe the development of cancer therapeutics begins with a clear understanding of the molecular characteristics and diversity of cancer patients."
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to curing cancers through the application of genomic data by providing researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. Visit www.compendiabio.com for more information.
Oncomine combines a rapidly growing compendium of 62,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and powerful web applications for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. Visit www.oncomine.com for more information.
About H3 Biomedicine Inc.
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit www.H3biomedicine.com for more information.
About Eisai Inc.
Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.
SOURCE Compendia Bioscience, Inc.